Literature DB >> 11937250

A cost-minimising analysis of standard radiotherapy and two experimental therapies in glioblastoma.

Tom B Johannesen1, Jan Norum, Knut Lote, David Scheie, Henry Hirschberg.   

Abstract

BACKGROUND AND
PURPOSE: Accelerated radiotherapy (ART) and intracavity brachytherapy (ICBT) have been introduced in the primary treatment of glioblastoma. Our objective was to determine total treatment costs, hospitalisation time, and treatment outcome in these two experimental therapies compared to standard treatment.
MATERIALS AND METHODS: In the time period 1985 to 1st May 1999, a total of 174 patients with histologically confirmed glioblastoma multiforme were given postoperative radiotherapy according to three different treatment schedules at three different time intervals. A conventional regime of external radiotherapy (54Gy/30 fractions) was given to 58 patients (group I), 75 patients were treated with ART (48Gy/twice daily 30 fractions) (group II), and 41 patients were given ICBT (60Gy/ten fractions) (group III). Treatment costs including surgery, hospital stay, hospital hotel stay, and radiotherapy were calculated.
RESULTS: The total mean costs employing the three treatment alternatives were calculated to $25,618 (group I), $23,442 (group II), and $14,534 (group III). Total mean stay in hospital for the whole primary treatment was 48.8, 41.6, and 19 days for groups I, II, and III respectively. Median survival figures were 16, 14, and 13 months for groups I, II, and III, respectively.
CONCLUSIONS: The total cost of postoperative radiotherapy in glioblastoma is comparable to other health care services. ART did not improve the total treatment cost or influence the need for hospitalisation compared to standard treatment. ICBT seemed to have economic benefits with less need for hospitalisation.

Entities:  

Mesh:

Year:  2002        PMID: 11937250     DOI: 10.1016/s0167-8140(01)00495-9

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Quality-adjusted life years in glioma patients: a systematic review on currently available data and the lack of evidence-based utilities.

Authors:  Vicki Marie Butenschoen; Anna Kelm; Bernhard Meyer; Sandro M Krieg
Journal:  J Neurooncol       Date:  2019-06-12       Impact factor: 4.130

2.  Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.

Authors:  K Sköld; T Gorlia; L Pellettieri; V Giusti; B H-Stenstam; J W Hopewell
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

3.  Economics of Malignant Gliomas: A Critical Review.

Authors:  Jeffrey J Raizer; Karen A Fitzner; Daniel I Jacobs; Charles L Bennett; Dustin B Liebling; Thanh Ha Luu; Steven M Trifilio; Sean A Grimm; Matthew J Fisher; Meraaj S Haleem; Paul S Ray; Judith M McKoy; Rebecca DeBoer; Katrina-Marie E Tulas; Mohammed Deeb; June M McKoy
Journal:  J Oncol Pract       Date:  2014-12-02       Impact factor: 3.840

4.  Pilot Feasibility Study of an Oncology Financial Navigation Program in Brain Cancer Patients.

Authors:  Gelareh Sadigh; Kathleen Gallagher; Jennifer Obenchain; Al Benson; Edith Mitchell; Soma Sengupta; Ruth C Carlos
Journal:  J Am Coll Radiol       Date:  2019-10       Impact factor: 5.532

5.  Photodynamic therapy mediated immune therapy of brain tumors.

Authors:  Henry Hirschberg; Kristian Berg; Qian Peng
Journal:  Neuroimmunol Neuroinflamm       Date:  2018-07-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.